CA2842355A1 - Pentamidine amidoxime acid esters as prodrugs and use thereof as drugs - Google Patents

Pentamidine amidoxime acid esters as prodrugs and use thereof as drugs Download PDF

Info

Publication number
CA2842355A1
CA2842355A1 CA2842355A CA2842355A CA2842355A1 CA 2842355 A1 CA2842355 A1 CA 2842355A1 CA 2842355 A CA2842355 A CA 2842355A CA 2842355 A CA2842355 A CA 2842355A CA 2842355 A1 CA2842355 A1 CA 2842355A1
Authority
CA
Canada
Prior art keywords
pentamidine
compound according
bis
prodrugs
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2842355A
Other languages
English (en)
French (fr)
Inventor
Bernd Clement
Joscha KOTTHAUS
Jurke Kotthaus
Dennis Schade
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dritte Patentportfolio Beteiligungs GmbH and Co KG
Original Assignee
Dritte Patentportfolio Beteiligungs GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dritte Patentportfolio Beteiligungs GmbH and Co KG filed Critical Dritte Patentportfolio Beteiligungs GmbH and Co KG
Publication of CA2842355A1 publication Critical patent/CA2842355A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/12—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
    • C07C259/18—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxamidine groups bound to carbon atoms of six-membered aromatic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2842355A 2011-07-25 2012-07-19 Pentamidine amidoxime acid esters as prodrugs and use thereof as drugs Abandoned CA2842355A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11175252.3 2011-07-25
EP11175252.3A EP2550963B1 (de) 2011-07-25 2011-07-25 Pentamidin-Amidoximsäureesters als Prodrugs und ihre Verwendung als Arzneimittel
PCT/EP2012/064171 WO2013014059A1 (de) 2011-07-25 2012-07-19 Pentamidin-amidoximsäureesters als prodrugs und ihre verwendung als arzneimittel

Publications (1)

Publication Number Publication Date
CA2842355A1 true CA2842355A1 (en) 2013-01-31

Family

ID=46514404

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2842355A Abandoned CA2842355A1 (en) 2011-07-25 2012-07-19 Pentamidine amidoxime acid esters as prodrugs and use thereof as drugs

Country Status (19)

Country Link
US (1) US20130085180A1 (enExample)
EP (1) EP2550963B1 (enExample)
JP (2) JP2014529579A (enExample)
KR (1) KR20140097108A (enExample)
CN (1) CN103874491A (enExample)
AU (1) AU2012288968B2 (enExample)
BR (1) BR112014001787A2 (enExample)
CA (1) CA2842355A1 (enExample)
DK (1) DK2550963T3 (enExample)
ES (1) ES2610652T3 (enExample)
HR (1) HRP20170013T1 (enExample)
HU (1) HUE030245T2 (enExample)
LT (1) LT2550963T (enExample)
PL (1) PL2550963T3 (enExample)
PT (1) PT2550963T (enExample)
RS (1) RS55557B1 (enExample)
RU (1) RU2608388C2 (enExample)
SI (1) SI2550963T1 (enExample)
WO (1) WO2013014059A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2894466A1 (en) 2012-12-21 2014-06-26 Patrick Colin Uses and methods for the treatment of liver diseases or conditions
EP3687514A4 (en) 2017-09-27 2021-06-30 Ohio State Innovation Foundation METHODS AND COMPOSITIONS FOR INHIBITING STAT3
US10835581B2 (en) 2017-11-28 2020-11-17 University of Pittsburgh—of the Commonwealth System of Higher Education Method of treating insulin resistance
US12398105B2 (en) * 2018-12-20 2025-08-26 Auransa Inc. Analogues of pentamidine and uses therefor
WO2024211870A2 (en) * 2023-04-07 2024-10-10 Auransa Inc. Pentamidine analogue polymorphs, formulations, and methods thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4321444A1 (de) * 1993-06-28 1995-01-05 Bernd Prof Dr Clement Pharmazeutische Zubereitung
US5723495A (en) * 1995-11-16 1998-03-03 The University Of North Carolina At Chapel Hill Benzamidoxime prodrugs as antipneumocystic agents
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
DE102008007381A1 (de) 2008-02-01 2009-08-13 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg Amidine und Guanidine und deren Derivate zur Behandlung von Krankheiten

Also Published As

Publication number Publication date
SI2550963T1 (sl) 2017-05-31
JP2014529579A (ja) 2014-11-13
RS55557B1 (sr) 2017-05-31
CN103874491A (zh) 2014-06-18
RU2014106867A (ru) 2015-08-27
KR20140097108A (ko) 2014-08-06
BR112014001787A2 (pt) 2017-02-21
HUE030245T2 (en) 2017-04-28
PL2550963T3 (pl) 2017-08-31
US20130085180A1 (en) 2013-04-04
PT2550963T (pt) 2017-01-19
AU2012288968A1 (en) 2014-02-13
EP2550963A1 (de) 2013-01-30
LT2550963T (lt) 2017-02-27
ES2610652T3 (es) 2017-04-28
JP2017039727A (ja) 2017-02-23
WO2013014059A1 (de) 2013-01-31
HRP20170013T1 (hr) 2017-03-10
AU2012288968B2 (en) 2017-01-05
EP2550963B1 (de) 2016-10-12
RU2608388C2 (ru) 2017-01-18
DK2550963T3 (en) 2017-01-30

Similar Documents

Publication Publication Date Title
AU2012288968B2 (en) Pentamidine amidoxime acid esters as prodrugs and use thereof as drugs
US10029956B2 (en) Therapies for cancer using isotopically substituted lysine
US8853245B2 (en) Orally bioavailable dabigatran prodrugs for the treatment of diseases
US20160362386A1 (en) Cystine diamide analogs for the prevention of cystine stone formation in cystinuria
US9662308B2 (en) Orally bioavailable pentamidine prodrugs for the treatment of diseases
JP6198741B2 (ja) インフルエンザを処置するための化合物
RU2550969C2 (ru) Способ улучшения биоактивации лекарственных веществ
CN112920105B (zh) 一种邻苯二甲酰亚胺类化合物及其制备方法和应用
AU2023429876A1 (en) Ptp1b/tc-ptp dual inhibitors and protein degraders
US20240239787A1 (en) Compounds for use in the treatment of cancer
US11203596B2 (en) Analogs of 3-amino-4-(propan-2-ylidene)cyclopentane-1-carboxylic acid and uses thereof for treating diseases and disorders associated with ornithine aminotransferase activity
RS50072B (sr) S-nitrozotioli kao agensi za tretman cirkulatornih poremećaja
US20250188083A1 (en) Modulators of Histone Acetyltransferase 1 and Methods of Treatment Thereof
CN108997230A (zh) 具有基质金属蛋白酶抑制活性的喹喔啉衍生物及其制备方法和应用
US20160194336A1 (en) P38 mapk inhibitors for the treatment of inflammatory diseases
JP4986335B2 (ja) Ｖｄａｃ機能阻害剤
EP4661890A1 (en) Ptp1b/tc-ptp dual inhibitors and protein degraders
CN118772216A (zh) 5-氟尿嘧啶核苷磷酰胺酯类化合物及其用途

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20180719